BACKGROUND: It has been shown that the partial N-methyl-d-aspartate (NMDA) agonist d-cycloserine (DCS) facilitates exposure-based learning in humans with anxiety disorders. However, the effects of DCS on exposure to substance cues are still uncertain. OBJECTIVE: The primary aim of the study was to examine the effects of DCS on exposure sessions to alcohol cues. METHODS:Twenty non-treatment-seeking problem drinkers were randomly assigned to receive 50 mg of DCS or placebo 50 minutes prior to each of 3 alcohol cue exposure sessions consisting of 5 exposure trials within an 8-day period. Following this, participants underwent two test sessions without the administration of any medication. The test sessions occurred 3 and 7 days after the last cue exposure session, respectively. Dependent measures included drinking urge and heart rate and drinking urge during the test sessions. RESULTS: Individuals who received DCS showed increased craving to alcohol cues as compared with individuals who received placebo during the first test session. No group difference in drinking urge was found during the second test session. Furthermore, the groups did not differ in heart rate at any of the assessment points. CONCLUSIONS: The results suggest that DCS may temporarily augment cue-elicited craving for alcohol. SCIENTIFIC SIGNIFICANCE: As in an earlier study with cocaine-dependent individuals, DCS appears to exhibit a different profile in problem drinkers to those with anxiety disorders. Dose, timing, arousal, and treatment motivation as considerations are discussed, as are methodological considerations and the need for additional studies in this area.
RCT Entities:
BACKGROUND: It has been shown that the partial N-methyl-d-aspartate (NMDA) agonist d-cycloserine (DCS) facilitates exposure-based learning in humans with anxiety disorders. However, the effects of DCS on exposure to substance cues are still uncertain. OBJECTIVE: The primary aim of the study was to examine the effects of DCS on exposure sessions to alcohol cues. METHODS: Twenty non-treatment-seeking problem drinkers were randomly assigned to receive 50 mg of DCS or placebo 50 minutes prior to each of 3 alcohol cue exposure sessions consisting of 5 exposure trials within an 8-day period. Following this, participants underwent two test sessions without the administration of any medication. The test sessions occurred 3 and 7 days after the last cue exposure session, respectively. Dependent measures included drinking urge and heart rate and drinking urge during the test sessions. RESULTS: Individuals who received DCS showed increased craving to alcohol cues as compared with individuals who received placebo during the first test session. No group difference in drinking urge was found during the second test session. Furthermore, the groups did not differ in heart rate at any of the assessment points. CONCLUSIONS: The results suggest that DCS may temporarily augment cue-elicited craving for alcohol. SCIENTIFIC SIGNIFICANCE: As in an earlier study with cocaine-dependent individuals, DCS appears to exhibit a different profile in problem drinkers to those with anxiety disorders. Dose, timing, arousal, and treatment motivation as considerations are discussed, as are methodological considerations and the need for additional studies in this area.
Authors: Michael W Otto; M Alexandra Kredlow; Jasper A J Smits; Stefan G Hofmann; David F Tolin; Rianne A de Kleine; Agnes van Minnen; A Eden Evins; Mark H Pollack Journal: Biol Psychiatry Date: 2015-09-25 Impact factor: 13.382
Authors: Michael W Otto; Gladys N Pachas; Corinne Cather; Susanne S Hoeppner; Samantha J Moshier; Bridget A Hearon; Heather Burrell Ward; Alexandra B Laffer; Jasper A J Smits; A Eden Evins Journal: Cogn Behav Ther Date: 2018-08-16
Authors: Falk Kiefer; Martina Kirsch; Patrick Bach; Sabine Hoffmann; Iris Reinhard; Anne Jorde; Christoph von der Goltz; Rainer Spanagel; Karl Mann; Sabine Loeber; Sabine Vollstädt-Klein Journal: Psychopharmacology (Berl) Date: 2015-02-21 Impact factor: 4.530
Authors: Jamie M Gauthier; Amy Lin; Bríd Á Nic Dhonnchadha; Roger D Spealman; Heng-Ye Man; Kathleen M Kantak Journal: Addict Biol Date: 2015-09-18 Impact factor: 4.280
Authors: Kathleen M Kantak; Jamie M Gauthier; Elon Mathieson; Eudokia Knyazhanskaya; Pedro Rodriguez-Echemendia; Heng-Ye Man Journal: Behav Brain Res Date: 2020-08-02 Impact factor: 3.332
Authors: M D Scofield; J A Heinsbroek; C D Gipson; Y M Kupchik; S Spencer; A C W Smith; D Roberts-Wolfe; P W Kalivas Journal: Pharmacol Rev Date: 2016-07 Impact factor: 25.468